Pharvaris (NASDAQ:PHVS) Price Target Raised to $79.00

Pharvaris (NASDAQ:PHVS) had its target price lifted by Citizens Jmp from $75.00 to $79.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

Other equities analysts also recently issued reports about the stock. Guggenheim boosted their target price on shares of Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Oppenheimer reiterated an “outperform” rating and issued a $75.00 price target on shares of Pharvaris in a research note on Tuesday. Morgan Stanley lifted their price objective on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a research note on Tuesday. Finally, Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.50.

Pharvaris Stock Up 1.4%

NASDAQ:PHVS opened at $38.02 on Wednesday. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -12.47 and a beta of -2.33. Pharvaris has a twelve month low of $20.65 and a twelve month high of $43.25. The stock’s 50 day moving average price is $35.09 and its two-hundred day moving average price is $31.38.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, analysts anticipate that Pharvaris will post -3.12 earnings per share for the current year.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the transaction, the insider directly owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This represents a 24.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the transaction, the director owned 315,167 shares in the company, valued at $11,185,276.83. The trade was a 8.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 141,655 shares of company stock worth $5,098,602 in the last 90 days. Company insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. Geode Capital Management LLC grew its stake in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc raised its stake in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi boosted its holdings in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares during the period.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
• Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
• Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.